Literature DB >> 2166141

Is chemotherapy for metastatic non-small cell lung cancer "worth it"?

J C Ruckdeschel1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2166141     DOI： 10.1200/JCO.1990.8.8.1293

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  3 in total

Review 1.  Second-line chemotherapy for non-small-cell lung cancer.

Authors:  F V Fossella
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

2.  Appraising the economic efficiency of cancer treatment: an exploratory analysis of lung cancer.

Authors:  Thomas N Chirikos
Journal:  Health Care Manag Sci       Date:  2003-05

3.  Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer.

Authors:  J H M Schellens; A S T Planting; N van Zandwijk; J Ma; M Maliepaard; M E L van der Burg; M de Boer-Dennert; E Brouwer; A van der Gaast; M J van den Bent; J Verweij
Journal:  Br J Cancer       Date:  2003-03-24       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.